Investigators analyze characteristics of participants with acquired partial lipodystrophy who developed severe metabolic abnormalities.
Genetic testing should become the standard of care for patients with definite or probable familial hypercholesterolemia.
A variety of underlying mechanisms may be attributed to the role of statins in preventing bone-related disorders.
Low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) ≥160 mg/dL are independently associated with increased relative risk of cardiovascular disease (CVD) mortality in a low-risk cohort.
"We are extremely disappointed with the FDA's decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS," said Akcea CEO, Paula Soteropoulos.
Serum 25-hydroxyvitamin D [25(OH)D] is independently and inversely associated with total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol in children.
Nutraceuticals may offer a solution to patients who cannot tolerate statins because of severe muscle pain.
There has been a substantial increase in the percentage of patients with high cholesterol over age 60 years taking lipid-lowering medications from 2005 to 2016, but such increases have not been seen among younger patients with high cholesterol.
Investigators revised pooled cohort equations to improve clinical accuracy to predict risk for cardiovascular disease.
Investigators examine the effects of the PCSK9 inhibitor alirocumab in patients with recent acute coronary syndrome and diabetes.
Investigators examined cardiovascular outcomes in patients with elevated triglyceridemia and diabetes treated with statins.
For this study, researchers investigated the pharmacodynamics of evolocumab in two Phase 2 placebo-controlled studies (MENDEL and LAPLACE-TIMI 57) in order to determine which dosing regimens provided the most consistent LDL-C reduction.
Using both public and private health insurance claims data, investigators conducted a retrospective cohort study to assess cardiovascular risk in the setting of diabetes and rheumatoid arthritis.
From 25% to 50% of patients discontinue statins within 6 months to 1 year of starting, and the rate increases as high as 75% after 2 years.
Multiple clinical studies have examined the efficacy of pitavastatin.
Reduced risk for hyperlipidemia with hydroxychloroquine vs. other disease-modifying antirheumatic drugs.
Researchers have discovered that a common medication indicated for the treatment of high cholesterol may stimulate the same peroxisome proliferator-activated receptors (PPARs) as cannabinoids, which could lead to a new class of cannabis-like drugs to treat a range of conditions.
Young adults with high cholesterol have an increased risk for developing coronary heart disease later in life.
Outcomes positive for nurse-managed protocols in patients with chronic conditions.
Endocrinology Advisor Articles
- Heritability of BMI Stronger in Obesogenic Environments
- Adverse Events Associated With Diazoxide Treatment for Congenital Hyperinsulinism
- Maternal Gluten Intake Associated With Risk for Type 1 Diabetes in Offspring
- Patterns of Evidence-Based Diabetes Interventions at Local Health Departments
- Bone-Derived Factors in the Treatment of Diabetes
- Vitamin D Supplementation Has No Effect on Musculoskeletal Health
- Deep Learning Algorithm Efficiently Detects Vision-Threatening Diabetic Retinopathy
- Industry-Funded Trials Often Involve Employees in Studies
- Nutrition Tips for Physicians: Staying Healthy During Busy Days
- Early-Onset Asthma/Wheezing Associated With Later Childhood Obesity